Cervical cancer
Conditions
Interventions
Control Group:None
Experimental Group:Sacral Neuromodulation (SNM)
Sponsors
Department of Gynecological Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200092, China
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Aged 20 to 80 years; 2. Stage IB1 to IIA1 cervical cancer (FIGO 2018 staging) treated with radical hysterectomy; 3. No indication for postoperative adjuvant chemoradiotherapy based on postoperative pathology; 4. No contraindications to SNM surgery; 5. Good compliance, willing and able to meet trial requirements; 6. Signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of pelvic radiotherapy; 2. Patients with a history of voiding dysfunction, urinary incontinence, or abnormal preoperative urodynamic findings; 3. Patients in whom lower urinary tract dysfunction due to other causes cannot be ruled out; 4. Patients with severe urinary tract infections or vesicovaginal fistula; 5. Patients with concomitant urinary system tumors, urinary calculi, or other obstructive uropathies; 6. Patients with impaired function of important organs: liver enzymes >2 times the upper limit of normal, creatinine >2 times the upper limit of normal, blood amylase >2 times the upper limit of normal, cardiac function class 3–4, etc; 7. Patients with psychiatric or cognitive impairments who are unable to cooperate with the trial process; 8. Other conditions deemed by the investigator as unsuitable for study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of urinary improvement at six months postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urodynamic parameters; | — |
Countries
China
Contacts
Public ContactXiaoqing Guo
Shanghai First Maternity and Infant Hospital
Outcome results
None listed